These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31384941)

  • 1. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.
    Potard V; Canestri A; Gallien S; Costagliola D;
    J Antimicrob Chemother; 2019 Nov; 74(11):3305-3314. PubMed ID: 31384941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France.
    Potard V; Gallien S; Canestri A; Costagliola D;
    J Antimicrob Chemother; 2021 Jan; 76(2):467-476. PubMed ID: 33257955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil.
    Santos AMRD; Martins AP; Juliato D; de Miranda ÉJFP; Lopes GISL; Brígido LFM; Vidal JE
    Int J STD AIDS; 2020 Sep; 31(10):967-975. PubMed ID: 32698729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
    Pujari S; Gaikwad S; Bele V; Joshi K; Dabhade D
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218759211. PubMed ID: 29473485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia.
    Teeraananchai S; Law M; Boettiger D; Mata N; Gupte N; Chan YL; Pham TN; Chaiwarith R; Ly PS; Chan YJ; Kiertiburanakul S; Khusuwan S; Zhang F; Yunihastuti E; Kumarasamy N; Pujari S; Azwa I; Somia IKA; Tanuma J; Ditangco R; Choi JY; Ng OT; Do CD; Gani Y; Ross J; Jiamsakul A;
    J Int AIDS Soc; 2022 Aug; 25(8):e25989. PubMed ID: 36028921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.
    Rutsaert S; De Spiegelaere W; De Clercq L; Vandekerckhove L
    J Antimicrob Chemother; 2019 Oct; 74(10):3030-3034. PubMed ID: 31314108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
    Guiguet M; Ghosn J; Duvivier C; Meynard JL; Gras G; Partisani M; Teicher E; Mahamat A; Rodenbourg F; Launay O; Costagliola D;
    AIDS; 2012 Nov; 26(18):2345-50. PubMed ID: 22695301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 13. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
    Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC;
    HIV Med; 2011 May; 12(5):299-307. PubMed ID: 20955357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
    Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
    J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure.
    Alberton F; Galli L; Lolatto R; Candela C; Gianotti N; Chiurlo M; Ranzenigo M; Strano M; Uglietti A; Castagna A
    Drug Des Devel Ther; 2024; 18():1153-1163. PubMed ID: 38618279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.